Oncology Journals review

Assessing the value of systemic Therapy and radiation therapy in Stage I Nodal Marginal Zone Lymphoma

Oncologyme  /  Mar 26, 2023

1679825195_031222-TN22-Lymphoma.png

In a large Propensity score matched retrospective study was conducted to assess the value of systemic Therapy and radiation therapy...

CheckMate 914 trial: adjuvant Immunotherapy in Renal Cell Carcinoma

Oncologyme  /  Apr 30, 2023

1682839037_270423-TN-RCC.png

In the phase 3 CheckMate 914 trial, Adjuvant #nivolumab plus #ipilimumab failed to improve the clinical outcomes in patients with...

Colonoscopy benefits in CRC screening

Oncologyme  /  Mar 26, 2023

1679825518_121222-TN22-CRC.png

Although #colonoscopy is widely used as a #screening test to detect colorectal cancer (#CRC), it is more invasive and resources...

DESTINY-Breast02 trial: Trastuzumab deruxtecan after failure on TDM-1, An Update

Oncologyme  /  Apr 30, 2023

1682841338_010523-TN23-BC.png

In the phase 3 DESTINY-Breast02 trial, #Trastuzumab deruxtecan (T-DXd) improved the PFS and OS in patients with HER2-positive metastatic breast...

Dexamethasone for dysnea treatment

Oncologyme  /  Feb 15, 2023

1676458428_palliative-1.png

Patients with cancer often suffer shortness of breath for different reasons. Many physicians prescribe empirical dexamethasone as a symptomatic treatment....

ECHELON-1 trial

Oncologyme  /  Feb 15, 2023

1676462585_Conjugate-1.png

The addition of #brentuximab_vedotin shows survival benefits in patients with previously untreated stage III or IV classic #Hodgkin’s_lymphoma. The ECHELON-1...

GeparOLA trial: Investigating the effectiveness of neoadjuvant Olaparib and Paclitaxel in treating early HER2-negative breast cancer with high homologous recombination deficiency (HRD).

May 07, 2023

1683445720_040523-TN23-BC.png

In the phase II GeparOLA trial, Neoadjuvant #Olaparib plus paclitaxel was not superior to Paclitaxel-carboplatin regarding long-term outcomes in patients...

In a phase III Indian study, the addition of weekly carboplatin significantly improved overall survival and event-free survival when added to a taxane-anthracycline neoadjuvant chemotherapy regimen for patients with locally advanced triple-negative breast cancer.

Oncologyme  /  Apr 30, 2023

In the phase 2, PACE trial, the combination of #palbociclib plus fulvestrant did not improve significantly PFS compared with fulvestrant...

KEYNOTE 355 trial

Oncologyme  /  Feb 15, 2023

1676460473_Keynote 1.png

Adding #pembrolizumab to chemotherapy resulted in significantly longer overall survival among patients with previously untreated advanced #triple_negative_breast_cancer whose tumors expressed...

PURE 01 trial: Neoadjuvant Pembrolizumab for Muscle-invasive Bladder Carcinoma

Oncologyme  /  Apr 30, 2023

1682838560_110423-TN23-GU.png

In the phase II PURE-01 trial, #neoadjuvant #pembrolizumab has shown to improve the clinical outcomes in patients with muscle-invasive #bladder...

  • 1
  • 2